The company was founded in 2009 in China with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines, and is an industry-leading high-tech biological products enterprise. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is currently mainly engaged in vaccine research, development, production and commercialization. The main commercialized and ongoing products are meningococcal conjugate vaccine, pneumococcal conjugate vaccine, component 100 DPT vaccine, recombinant polio vaccine, etc. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Collective, and the company has won various honors such as Tianjin Manufacturing Individual Champion Enterprise, Tianjin Specialized and New Small and Medium Enterprises, and Tianjin Advanced Smart Factory.